Ann: Updated Strategy and Investor Presentation, page-171

@Davisite, Daniel, based on the two Sheba trial results, Bisantrene worked miracles with EMD patients (this is, AML patients whose cancer has metastasised) and was pretty ordinary for non-EMD patients.

What if RAC's planned AML trial ends up including only or mostly non-EMD AML patients? will that be a fair test for Bisantrene's known powers?

…..

As I understand it, FTO gets especially over-expressed when cancer metastisises, and Bisantrene is very good at lowering FTO expression.

what if the “all comers” solid tumour trial ends up including mostly non-metastasised cancer patients? these would be the wrong patients to show up Bisantrene's special powers, wouldn’t they?

…

I am concerned about which patients you choose for your two trials. There are two issues here: speedy recruitment and selecting the right kind of patient.